Tower Research Capital LLC TRC Boosts Stake in National Research Co. (NASDAQ:NRC)

Tower Research Capital LLC TRC raised its position in National Research Co. (NASDAQ:NRC) by 376.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,507 shares of the company’s stock after purchasing an additional 1,981 shares during the quarter. Tower Research Capital LLC TRC’s holdings in National Research were worth $44,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in National Research by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 435,707 shares of the company’s stock worth $7,687,000 after acquiring an additional 14,974 shares in the last quarter. Renaissance Technologies LLC grew its stake in National Research by 6.6% in the 4th quarter. Renaissance Technologies LLC now owns 404,886 shares of the company’s stock worth $7,142,000 after acquiring an additional 25,002 shares in the last quarter. Bank of New York Mellon Corp grew its stake in National Research by 88.5% in the 4th quarter. Bank of New York Mellon Corp now owns 217,212 shares of the company’s stock worth $3,832,000 after acquiring an additional 101,957 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in National Research by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 124,711 shares of the company’s stock worth $2,200,000 after acquiring an additional 970 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its stake in National Research by 23.8% in the 4th quarter. Teacher Retirement System of Texas now owns 57,826 shares of the company’s stock worth $1,020,000 after acquiring an additional 11,105 shares in the last quarter. 47.26% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, major shareholder Patrick E. Beans bought 2,500 shares of the stock in a transaction on Monday, May 12th. The stock was bought at an average cost of $13.59 per share, for a total transaction of $33,975.00. Following the completion of the purchase, the insider now directly owns 35,003 shares in the company, valued at approximately $475,690.77. The trade was a 7.69% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 8.10% of the company’s stock.

National Research Price Performance

Shares of NRC stock opened at $13.44 on Wednesday. The company has a debt-to-equity ratio of 1.30, a current ratio of 0.47 and a quick ratio of 0.47. The company has a market capitalization of $308.39 million, a P/E ratio of 12.80 and a beta of 0.34. The company’s 50-day simple moving average is $12.74 and its two-hundred day simple moving average is $16.01. National Research Co. has a one year low of $9.76 and a one year high of $32.48.

National Research (NASDAQ:NRC) last issued its earnings results on Monday, April 28th. The company reported $0.25 EPS for the quarter. The business had revenue of $33.55 million for the quarter. National Research had a net margin of 17.32% and a return on equity of 66.52%.

National Research Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 11th. Stockholders of record on Friday, June 27th will be paid a dividend of $0.12 per share. The ex-dividend date is Friday, June 27th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 3.57%. National Research’s dividend payout ratio is presently 46.60%.

About National Research

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.